{"id":52292,"date":"2021-04-05T12:37:00","date_gmt":"2021-04-05T12:37:00","guid":{"rendered":"https:\/\/www.verificat.cat\/epivaccorona-work\/"},"modified":"2021-04-05T12:37:00","modified_gmt":"2021-04-05T12:37:00","slug":"epivaccorona-work","status":"publish","type":"post","link":"https:\/\/www.verificat.cat\/en\/epivaccorona-work\/","title":{"rendered":"EpiVacCorona"},"content":{"rendered":"<p><br \/>\n<\/p>\n<p>The second vaccine developed in Russia is EpiVacCorona. There is still little information about this vaccine, which has already been approved by the government, but as of 19 March <a href=\"https:\/\/www.bmj.com\/content\/372\/bmj.n743\" target=\"_blank\" rel=\"noopener\">was not yet being used<\/a> to immunise the population.&nbsp;<\/p>\n<p>Manufactured by the <a href=\"http:\/\/www.vector.nsc.ru\/\" target=\"_blank\" rel=\"noopener\">State Research Center of Virology and Biotechnology VECTOR<\/a>, EpiVacCorona is a vaccine based on <a href=\"https:\/\/www.who.int\/biologicals\/vaccines\/synthetic_peptide_vaccines\/en\/\" target=\"_blank\" rel=\"noopener\">synthetic peptides<\/a>. Its composition includes a synthetic version of SARS-CoV-2 protein fragments (or peptides) to trigger the immune response in the body. The <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04780035?term=vaccine&amp;cond=Covid19&amp;draw=2\" target=\"_blank\" rel=\"noopener\">phase III<\/a> clinical trial began in November 2020 and involved about <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04780035?term=vaccine&amp;cond=Covid19&amp;draw=2\" target=\"_blank\" rel=\"noopener\">3,000 volunteers<\/a> from <a href=\"https:\/\/covid19.trackvaccines.org\/vaccines\/32\/\" target=\"_blank\" rel=\"noopener\">Russia<\/a>. The results have not yet been published, but officials assured that it offered <a href=\"https:\/\/tass.com\/science\/1246703\" target=\"_blank\" rel=\"noopener\">100% efficacy<\/a> during phases I and II. It consists of <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04780035\" target=\"_blank\" rel=\"noopener\">two doses<\/a>, administered over <a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04780035?term=vaccine&amp;cond=Covid19&amp;draw=2\" target=\"_blank\" rel=\"noopener\">21 to 28 days<\/a>.&nbsp;<\/p>\n<p>It is not known at this stage whether it causes adverse reactions and there is no information on the temperature at which it should be stored.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The second vaccine developed in Russia is EpiVacCorona. There is  [&#8230;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[169],"tags":[208],"class_list":["post-52292","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-vaccines-en","vc-legacy-post"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/comments?post=52292"}],"version-history":[{"count":0,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52292\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/media?parent=52292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/categories?post=52292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/tags?post=52292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}